Jed Abraham Katzel, MD
Hematology/Oncology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Katzel’s office at (415) 833-2200 to ask if they take your plan before you enroll.
California Medical Board record
Licence A109319 · Current
Licensed to practise in California · since 2009 · expires 2028-11-30 · Pennsylvania State University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$2,370,994
Pharmacies billed $2,370,994 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
184 generic and 157 brand-name prescriptions · $2,370,994 in drug cost · 15 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 86 | $1,504,951 | $17,499 |
| Brukinsa | 18 | $236,733 | $13,152 |
| Alecensa | 12 | $120,876 | $10,073 |
| Erlotinib | 11 | $721 | $66 |
| Dexamethasone | 40 | $463 | $12 |
See all 8 drugs
| Tagrisso | 86 | $1,504,951 | $17,499 |
| Brukinsa | 18 | $236,733 | $13,152 |
| Alecensa | 12 | $120,876 | $10,073 |
| Erlotinib | 11 | $721 | $66 |
| Dexamethasone | 40 | $463 | $12 |
| Ondansetron | 31 | $262 | $8 |
| Olanzapine | 17 | $119 | $7 |
| Ondansetron Odt | 11 | $119 | $11 |
Year by year
| 2024 | 341 | 88 | None | 46% | $2,370,994 |
| 2023 | 425 | 101 | None | None | $3,160,683 |
| 2022 | 333 | 84 | None | 53% | $2,859,205 |
| 2021 | 365 | 83 | None | 46% | $2,659,195 |
| 2020 | 292 | 63 | None | 55% | $2,352,637 |
| 2019 | 400 | 74 | None | 53% | $2,493,960 |
| 2018 | 416 | 82 | None | 47% | $1,766,165 |
| 2017 | 417 | 81 | None | 41% | $1,508,497 |
| 2016 | 503 | 104 | 4% (22) | 33% | $1,188,586 |
| 2015 | 546 | 102 | 4% (21) | 31% | $1,006,030 |
| 2014 | 460 | 96 | 4% (18) | 34% | $996,641 |
| 2013 | 495 | 106 | 3% (16) | None | $760,090 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Tagrisso | 146 | $2,352,625 | $16,114 |
| Alecensa | 12 | $114,585 | $9,549 |
| Erlotinib | 14 | $1,145 | $82 |
| Dexamethasone | 46 | $954 | $21 |
| Ondansetron | 38 | $308 | $8 |
| Prednisone | 17 | $281 | $17 |
| Prochlorperazine Maleate | 15 | $204 | $14 |
| Ondansetron Odt | 15 | $166 | $11 |
| Olanzapine | 13 | $84 | $6 |
2022: 6 drugs
| Tagrisso | 109 | $1,859,553 | $17,060 |
| Lenvima | 14 | $272,987 | $19,499 |
| Alecensa | 11 | $134,644 | $12,240 |
| Erlotinib | 12 | $1,809 | $151 |
| Dexamethasone | 35 | $1,138 | $33 |
| Ondansetron | 41 | $367 | $9 |
2021: 6 drugs
| Tagrisso | 100 | $1,698,103 | $16,981 |
| Alecensa | 12 | $148,906 | $12,409 |
| Imatinib Mesylate | 15 | $2,304 | $154 |
| Dexamethasone | 37 | $1,266 | $34 |
| Ondansetron | 50 | $545 | $11 |
| Prochlorperazine Maleate | 15 | $334 | $22 |
2020: 8 drugs
| Tagrisso | 73 | $1,306,292 | $17,894 |
| Alecensa | 17 | $268,300 | $15,782 |
| Vizimpro | 12 | $170,506 | $14,209 |
| Abiraterone Acetate | 12 | $3,985 | $332 |
| Imatinib Mesylate | 13 | $2,089 | $161 |
| Dexamethasone | 24 | $958 | $40 |
| Ondansetron | 26 | $295 | $11 |
| Diphenoxylate-Atropine | 12 | $257 | $21 |
2019: 12 drugs
| Tagrisso | 56 | $872,417 | $15,579 |
| Xtandi | 35 | $344,518 | $9,843 |
| Revlimid | 18 | $296,329 | $16,463 |
| Alecensa | 15 | $241,794 | $16,120 |
| Iressa | 11 | $89,073 | $8,098 |
| Abiraterone Acetate | 15 | $27,407 | $1,827 |
| Exemestane | 11 | $3,347 | $304 |
| Imatinib Mesylate | 12 | $2,835 | $236 |
| Dexamethasone | 17 | $990 | $58 |
| Hydroxyurea | 15 | $931 | $62 |
| Bicalutamide | 12 | $236 | $20 |
| Ondansetron | 22 | $210 | $10 |
2018: 12 drugs
| Xtandi | 63 | $508,638 | $8,074 |
| Revlimid | 24 | $371,863 | $15,494 |
| Zytiga | 16 | $166,725 | $10,420 |
| Tarceva | 16 | $119,707 | $7,482 |
| Iressa | 12 | $96,233 | $8,019 |
| Imatinib Mesylate | 26 | $10,971 | $422 |
| Hydroxyurea | 17 | $1,716 | $101 |
| Dexamethasone | 20 | $850 | $43 |
| Diphenoxylate-Atropine | 17 | $788 | $46 |
| Prednisone | 16 | $298 | $19 |
| Prochlorperazine Maleate | 17 | $165 | $10 |
| Ondansetron | 11 | $164 | $15 |
2017: 10 drugs
| Xtandi | 48 | $464,693 | $9,681 |
| Revlimid | 26 | $359,875 | $13,841 |
| Tarceva | 23 | $178,342 | $7,754 |
| Hydroxyurea | 20 | $2,012 | $101 |
| Diphenoxylate-Atropine | 16 | $942 | $59 |
| Bicalutamide | 17 | $581 | $34 |
| Dexamethasone | 30 | $517 | $17 |
| Acyclovir | 18 | $446 | $25 |
| Ondansetron | 22 | $321 | $15 |
| Prochlorperazine Maleate | 29 | $297 | $10 |
2016: 14 drugs
| Revlimid | 25 | $294,788 | $11,792 |
| Tarceva | 39 | $262,132 | $6,721 |
| Afinitor | 13 | $165,339 | $12,718 |
| Xtandi | 12 | $117,085 | $9,757 |
| Hydroxyurea | 20 | $1,930 | $97 |
| Acyclovir | 40 | $1,145 | $29 |
| Diphenoxylate-Atropine | 21 | $904 | $43 |
| Dexamethasone | 20 | $581 | $29 |
| Bicalutamide | 13 | $532 | $41 |
| Anastrozole | 15 | $516 | $34 |
| Hydrocodone-Acetaminophen | 12 | $490 | $41 |
| Ondansetron | 29 | $469 | $16 |
| Prochlorperazine Maleate | 39 | $446 | $11 |
| Prednisone | 16 | $443 | $28 |
2015: 13 drugs
| Revlimid | 15 | $160,578 | $10,705 |
| Tarceva | 15 | $94,162 | $6,277 |
| Lovenox | 19 | $14,205 | $748 |
| Fluconazole | 13 | $2,354 | $181 |
| Doxycycline Monohydrate | 20 | $1,212 | $61 |
| Anastrozole | 31 | $1,086 | $35 |
| Acyclovir | 31 | $885 | $29 |
| Ondansetron | 45 | $740 | $16 |
| Prednisone | 28 | $621 | $22 |
| Hydrocodone-Acetaminophen | 12 | $605 | $50 |
| Prochlorperazine Maleate | 40 | $454 | $11 |
| Dexamethasone | 12 | $286 | $24 |
| Lorazepam | 22 | $205 | $9 |
2014: 14 drugs
| Zytiga | 23 | $157,688 | $6,856 |
| Inlyta | 15 | $154,267 | $10,284 |
| Sprycel | 11 | $116,902 | $10,627 |
| Xtandi | 13 | $110,751 | $8,519 |
| Lovenox | 20 | $14,969 | $748 |
| Emend | 13 | $6,080 | $468 |
| Anastrozole | 37 | $1,303 | $35 |
| Doxycycline Monohydrate | 17 | $964 | $57 |
| Acyclovir | 20 | $706 | $35 |
| Letrozole | 14 | $573 | $41 |
| Hydrocodone-Acetaminophen | 11 | $570 | $52 |
| Prochlorperazine Maleate | 35 | $545 | $16 |
| Prednisone | 19 | $372 | $20 |
| Lorazepam | 26 | $234 | $9 |
2013: 15 drugs
| Sprycel | 13 | $122,123 | $9,394 |
| Afinitor | 14 | $118,381 | $8,456 |
| Zytiga | 14 | $79,694 | $5,692 |
| Emend | 16 | $6,872 | $429 |
| Anastrozole | 35 | $1,343 | $38 |
| Letrozole | 23 | $886 | $39 |
| Ketoconazole | 13 | $719 | $55 |
| Acyclovir | 16 | $607 | $38 |
| Prochlorperazine Maleate | 32 | $334 | $10 |
| Omeprazole | 12 | $265 | $22 |
| Nystatin | 13 | $260 | $20 |
| Ondansetron | 15 | $255 | $17 |
| Prednisone | 17 | $242 | $14 |
| Lorazepam | 12 | $96 | $8 |
| Trazodone | 11 | $96 | $9 |
Money from drug and device companies
$21 in 2025
A payment is not proof that care is biased.
| Teleflex | Arrow | $21 | 1 payment
|
See the published payment
| Teleflex | Meals · 2025-07-17 | Arrow | $21 |
Professional record
- NPI
- 1700012770
- Licence
- CA A109319, NY 237353California A109319: Current · expires 2028-11-30
- Trained
- Pennsylvania State University College of Medicine, 2002
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Internal medicine (207R00000X)
- Mailing address
- 710 Lawrence Expy, Oncology Department #440, Santa Clara, CA, 95051
- NPI first listed
- 2009-06-04
- NPI last updated
- 2026-07-29
- NPI record certified
- 2026-07-29
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.